Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• EQ504 has potential to be a first-in-class, oral and colon-targeted therapeutic for ulcerative colitis

  80% confidence

• Initial tranche of financing is expected to fund Company operations through 2027

  80% confidence

• AhR modulation is a differentiated and multi-modal approach to decreasing tissue inflammation while promoting tissue repair

  80% confidence

• Cash and cash equivalents on the balance sheet as of September 30, 2025 are capable of funding currently planned operations through 2027

  80% confidence

• Equillium expects to be ready to initiate Phase 1 clinical study in mid-2026 with potential to achieve proof-of-concept with addition of UC patient cohorts following SAD/MAD portion

  80% confidence

• EQ504 is a potent and selective AhR modulator that may be administered orally and is formulated to target the colon, representing a next-generation therapeutic to treat UC locally

  80% confidence

• EQ504 has broad therapeutic potential in UC as a potential standalone oral therapy, or in combination with other therapeutic approaches

  80% confidence

• AhR modulation is clinically validated in skin and GI diseases through VTAMA and botanical indigo naturalis

  80% confidence

Cited in these Via News reports

• AI-Designed Drug Candidates Show Clinical Progress Across US and Canadian Trials →
• Apollo Drops 9% as Global Private Equity Pivots to Fee-Based Models →
• Apollo Drops 9% as Private Equity Faces Global Rate Pressure and Credit Market Uncertainty →
• Biotech Firms Secure Capital as Gene Therapy Trials Target 5 Million Global Patients with Dry AMD →
• Bitcoin Could Hit $10M as VCs Reframe Crypto as Global Settlement Infrastructure →
• Global Healthcare VCs Deploy $2B+ Across Clinical Assets While AI Mega-Rounds Concentrate in US Market →
• Private Equity Deploys $23B Into Global Energy Infrastructure as Transition Investment Accelerates →
• Private Equity Deploys $25B+ Into Energy Infrastructure as Global Transition Creates Asset Rush →
• Private Equity Firms Cut Deal Activity 75% While Biotech Bets Double Amid Global Market Volatility →
• Tikehau Capital Projects 45-50% Margins by 2029 as European Private Equity Shifts to Performance Fees →
• Tikehau Capital Sets €60bn Target as Global PE Firms Reshape Portfolios →
• Tikehau Capital Targets €60bn AUM by 2029 as European Private Equity Attracts Global Institutional Capital →
• Traditional VCs Reclaim 80% of Major Deals as Tiger Global, SoftBank Cut Activity 95% Globally →
• Venture Funds Extend to 18-Year Terms as Global Capital Markets Reset →
• Venture LPs Turn to Collateralized Loans as Secondary Markets Demand 60% Discounts Globally →